Evidence map›Paper›PMID 34394958›Full record

ArticleActa radiologica open2021

The feasibility of transcatheter arterial chemoembolization following radiation therapy for hepatocellular carcinoma.

Mostafa Hamada, Eisuke Ueshima, Takeaki Ishihara, Yutaka Koide, Takuya Okada, Hiroki Horinouchi, Jun Ishida, Hiroshi Mayahara, Koji Sasaki, Tomoyuki Gentsu and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta radiologica open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Mostafa HamadaDepartment of Radiology, Kobe University Graduate School of Medicine, Kobe, Japan.ORCID https://orcid.org/0000-0002-6024-239X
Eisuke UeshimaDepartment of Radiology, Kobe University Graduate School of Medicine, Kobe, Japan.ORCID https://orcid.org/0000-0001-8802-8793
Takeaki IshiharaDepartment of Radiation Oncology, Kobe University Graduate School of Medicine, Kobe, Japan.
Yutaka KoideDepartment of Radiology, Hyogo Brain and Heart Center at Himeji, Japan.
Takuya OkadaDepartment of Radiology, Kobe University Graduate School of Medicine, Kobe, Japan.ORCID https://orcid.org/0000-0003-4393-0382
Hiroki HorinouchiDepartment of Radiology, National Cerebral and Cardiovascular Center, Suita, Japan.
Jun IshidaDepartment of Radiology, Kobe Minimally-Invasive Cancer Center, Kobe, Japan.
Hiroshi MayaharaDepartment of Radiation Oncology, Kobe Minimally Invasive Cancer Center, Kobe, Japan.
Koji SasakiDepartment of Radiology, Kobe University Graduate School of Medicine, Kobe, Japan.
Tomoyuki GentsuDepartment of Radiology, Kobe University Graduate School of Medicine, Kobe, Japan.
Keitaro SofueDepartment of Radiology, Kobe University Graduate School of Medicine, Kobe, Japan.
Masato YamaguchiDepartment of Radiology, Kobe University Graduate School of Medicine, Kobe, Japan.
Ryohei SasakiDepartment of Radiation Oncology, Kobe University Graduate School of Medicine, Kobe, Japan.
Koji SugimotoDepartment of Radiology, Kobe University Graduate School of Medicine, Kobe, Japan.
Takamichi MurakamiDepartment of Radiology, Kobe University Graduate School of Medicine, Kobe, Japan.
Kobe University · JPKobe Medical Center · JPHyogo Brain and Heart Center · JPNational Cerebral and Cardiovascular Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTechnological developments have led to an increased usage of external-body radiotherapy (RT) for the treatment of hepatocellular carcinoma (HCC). Transcatheter arterial chemoembolization (TACE) may be required later in patients treated with RT because of the high recurrence rate and multinodular presentation of HCC. However, despite the risk of liver function impairment, the cumulative liver damage correlated with TACE following a hepatic RT has not been adequately assessed. PURPOSE: To evaluate the feasibility of TACE following RT for HCC. MATERIALS AND

methodsSixty-seven patients with HCC who underwent TACE after RT were retrospectively evaluated between 2012 and 2018. We assessed increases in Child-Turcotte-Pugh (CTP) by ≥2 points at 1 month, the incidence of major complications, survival duration, and short-term mortality within 6 months after TACE. Furthermore, we evaluated the predictive factors for liver function impairment and short-term mortality.

resultsEight patients experienced a CTP increase ≥2 points at 1 month. There were no cases of liver abscesses or bilomas. Nine patients died within 6 months following TACE. The mean liver dose (MLD) was a significant predictor of liver function impairment at 1 month (

conclusionsDespite the feasibility of TACE following RT, clinicians should pay attention to impaired pretreatment liver function, following high dose RT, and the short duration between RT and TACE.

Indexed as

chemoembolizationHepatocellular carcinomaliver dysfunctionradiation therapy

Identifiers

PMID34394958
PMCPMC8358533
OpenAlexW3187949734

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.